SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: Merck's office in South San Francisco, California
Pharm Country
Merck to Start Trials of New HPV Vaccine and Single-Dose Gardasil Shot
Merck is looking to expand its offerings in the human papillomavirus space with a new vaccine and to study a single-shot variant of Gardasil 9, both of which will start trials toward the end of 2024.
March 14, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: 3D illustration of antibody-drug conjugates carrying toxic payloads
ADC Biotech Tubulis Closes Upsized $138M Financing Round
The German biotech Thursday said the proceeds from the Series B2 round will support clinical evaluation of its lead solid tumor antibody-drug conjugate candidates and expansion into the U.S.
March 14, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Exterior of the FDA headquarters in Mary
Policy
FDA Raises Safety Concerns About BMS, J&J CAR-T Therapies Ahead of Adcomm
With an advisory committee meeting slated for Friday, the regulator has posted briefing documents in which it has raised concerns about early deaths in patients treated with Bristol Myers Squibb’s Abecma and Johnson & Johnson’s Carvykti.
March 13, 2024
 · 
2 min read
 · 
Tyler Patchen
Novartis' office building in Marburg, Germany
Deals
Novartis Buys IFM Due in Potential $835M Deal, Gains Access to Antagonist Program
IFM Therapeutics announced Wednesday its subsidiary IFM Due has been acquired by Novartis. The acquisition provides the Swiss pharma with full rights to IFM Due’s portfolio of STING antagonists targeting inflammation-driven diseases.
March 13, 2024
 · 
1 min read
 · 
Tyler Patchen
A Year After Silicon Valley Bank’s Collapse, Biotech Looks Back on the Crisis
Silicon Valley Bank was one of the primary lending institutions for biotech. A year after its demise, the industry has recovered, but lessons have been learned and scars remain.
March 12, 2024
 · 
4 min read
 · 
Tyler Patchen
Pictured: Boehringer Ingelheim's office in California
Business
Boehringer, Sosei Ink Potential $732M Deal for Schizophrenia Treatment
Boehringer Ingelheim has paid $27.3 million upfront to Sosei Heptares to develop a small molecule agonist of GPR52 to treat the positive, negative and cognitive symptoms of schizophrenia.
March 11, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Novo Nordisk's corporate headquarters in Denmark
FDA
FDA Approves Novo’s Obesity Drug Wegovy to Reduce Cardiovascular Events
Novo Nordisk’s blockbuster weight-loss drug Wegovy was approved on Friday by the FDA to reduce the risk of cardiovascular death, heart attack and stroke in adults who have cardiovascular disease and are obese or overweight.
March 8, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Fresenius Kabi's office in Toronto iStoc
FDA
Fresenius Kabi’s Biosimilar for Actemra Gets FDA Approval
According to Fresenius Kabi, Tyenne is the first biosimilar to Genentech’s Acterma which has both IV and subcutaneous formulations approved by the FDA.
March 8, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: A building at the headquarters of scienc
Drug Development
Merck KGaA Puts the Kibosh on BTK Inhibitor After Phase III MS Flops
The company announced Thursday it terminated its BTK inhibitor evobrutinib for multiple sclerosis, which did not meet the primary endpoints in two late-stage trials.
March 8, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: FDA sign at Washington D.C. headquarters
Drug Development
MindMed Gets Breakthrough Designation for LSD Candidate in Anxiety
MindMed’s stock price jumped over 50% Thursday as its LSD-based candidate for generalized anxiety disorder got a breakthrough therapy designation from the FDA.
March 8, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Gilead's headquarters in Silicon Valley/
Business
Gilead, Merus Ink Potential $1.5B Deal for T-Cell Engagers
Gilead Sciences is partnering with Dutch biotech Merus to find novel dual tumor-associated antigens that target tri-specific antibodies.
March 7, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Alnylam headquarters in Cambridge, Massa
Drug Development
Alnylam’s Zilebesiran Shows Positive Phase II Results in Reducing Blood Pressure
A mid-stage study of Alnylam Therapeutics’ experimental RNAi-based drug to treat hypertension met its primary endpoint.
March 6, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: a young boy with an oxygen mask/iStock,
Drug Development
Sionna Closes $182M Series C in Potential Cystic Fibrosis Showdown with Vertex
Sionna Therapeutics on Wednesday announced it raised another round of funding as the company looks to challenge Vertex Pharmaceuticals’ dominant cystic fibrosis business.
March 6, 2024
 · 
2 min read
 · 
Tyler Patchen
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now
These days you can hardly move without figuratively bumping into ⁠antibody-drug conjugates⁠ (ADCs). This week we discuss ⁠Pfizer’s strategic priorities⁠ for oncology - focused on ADCs and less on small molecules - and how the market is being influenced by the IRA.
March 6, 2024
 · 
1 min read
 · 
Lori Ellis
Pictured: Illustration showing a downward graph tr
Deals
Biopharma VC Funding Value Dropped Nearly 20% in Q4 2023: Pitchbook
Companies inked 204 deals in the fourth quarter of 2023 with venture capital funding slipping to $6.3 billion from $7.8 billion in the third quarter last year, according to market data firm Pitchbook.
March 5, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More